These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15105795)

  • 21. Safety and efficacy of a new oral contraceptive containing drospirenone.
    Shulman LP
    J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS; Jick H
    Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The androgenicity of oral contraceptives: the young patient's concerns.
    Runnebaum B
    Int J Fertil; 1992; 37 Suppl 4():211-7. PubMed ID: 1362188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Side effects of third generation progestagens].
    Sitruk-ware R
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):295-300. PubMed ID: 12318229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yasmin: the reason why.
    Thorneycroft IH
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
    Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
    Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical study of two monophase oral contraceptives with desogestrel].
    Uchikova E; Milchev N; Markova D; Batashki I; Gŭrova A
    Akush Ginekol (Sofiia); 2007; 46(2):18-21. PubMed ID: 17469446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial.
    Jaisamrarn U; Chaovisitsaree S; Angsuwathana S; Nerapusee O
    Contraception; 2014 Nov; 90(5):535-41. PubMed ID: 25074072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
    Cole JA; Norman H; Doherty M; Walker AM
    Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database.
    Murphy PA; Brixner D
    Contraception; 2008 Apr; 77(4):257-63. PubMed ID: 18342648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Less estrogen in new oral contraceptive.
    Am J Nurs; 2003 Apr; 103(4):111-2. PubMed ID: 12677126
    [No Abstract]   [Full Text] [Related]  

  • 33. Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives.
    Hampton RM; Zhang HF; Barnowski C; Wan GJ
    Contraception; 2008 Jun; 77(6):415-9. PubMed ID: 18477490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins.
    Speroff L; DeCherney A
    Obstet Gynecol; 1993 Jun; 81(6):1034-47. PubMed ID: 8497347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
    Olson WH; Lippman JS; Robisch DM
    Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
    Radowicki S; Skórzewska K; Szlendak K
    Ginekol Pol; 2005 Nov; 76(11):884-9. PubMed ID: 16566363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in oral hormonal contraception.
    Elstein M; Furniss HA
    Zentralbl Gynakol; 1995; 117(11):559-65. PubMed ID: 8533489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study.
    Burchardt NA; Eliassen AH; Shafrir AL; Rosner B; Tamimi RM; Kaaks R; Tworoger SS; Fortner RT
    Am J Obstet Gynecol; 2022 Jun; 226(6):821.e1-821.e26. PubMed ID: 34921803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study.
    Cagnacci A; Ferrari S; Tirelli A; Zanin R; Volpe A
    Contraception; 2009 Jul; 80(1):34-9. PubMed ID: 19501213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.